<DOC>
	<DOCNO>NCT02867709</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability 2 dos ubrogepant ( 25 50 mg ) compare placebo acute treatment single migraine attack .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Oral Ubrogepant Acute Treatment Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>At least 1year history migraine without aura consistent diagnosis accord International Classification Headache Disorders , 3rd edition , beta version Migraine onset age 50 History migraine typically last 4 72 hour untreated treat unsuccessfully migraine episode separate least 48 hour headache pain freedom History 2 8 migraine attack per month moderate severe headache pain previous 3 month . Difficulty distinguish migraine headache tensiontype headache Has take medication acute treatment headache ( include acetaminophen , nonsteroidal antiinflammatory drug [ NSAIDs ] , triptans , ergotamine , opioids , combination analgesic ) 10 day per month previous 3 month Has history migraine aura diplopia impairment level consciousness , hemiplegic migraine , retinal migraine Has current diagnosis new persistent daily headache , trigeminal autonomic cephalgia ( eg , cluster headache ) , painful cranial neuropathy Required hospital treatment migraine attack 3 time previous 6 month Has chronic nonheadache pain condition require daily pain medication Has history malignancy prior 5 year , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer Has history prior gastrointestinal condition ( eg , diarrhea syndrome , inflammatory bowel disease ) may affect absorption metabolism investigational product ; patient prior gastric bariatric intervention reverse exclude Has history hepatitis within previous 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>